Photo of Heidi S Feiler, Ph.D., M.A.

Heidi S Feiler Ph.D., M.A.

  • (503) 494-7707
    • Research Associate Professor of Biomedical Engineering School of Medicine
    • Scientific Program Manager OHSU Center for Spatial Systems Biomedicine School of Medicine

Dr. Feiler's research has focused on exploration of the mechanisms by which genomic, transcriptional and proteomic abnormalities occur in selected cancers, and the elucidation of how these abnormalities contribute to cancer pathophysiologies and influence response to gene targeted therapies.


  • Heiser, L.M., Sadanandam, A., Kuo, W.L., Benz, S.C., Goldstein, T.C., Ng, S., Gibb, W.J., Wang, N.J., Ziyad, S., Tong, F., Bayani, N., Hu, Z., Billig, J.I., Dueregger, A., Lewis, S., Jakkula, L., Korkola, J.E., Durinck, S., Pepin, F., Guan, Y., Purdom, E., Neuvial, P., Bengtsson, H., Wood, K.W., Smith, P.G., Vassilev, L.T., Hennessy, B.T., Greshock, J., Bachman, K.E., Hardwicke, M.A., Park, J.W., Marton, L.J., Wolf, D.M., Collisson, E.A., Neve, R.M., Mills, G.B., Speed, T.P., Feiler, H.S., Wooster, R.F., Haussler, D., Stuart, J.M., Gray, J.W., Spellman, P.T. (2012) Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc. Natl. Acad. Sci. USA. 109(8):2724-2729. PMC3286973.

  • Collisson, E.A., Sadanandam, A., Olson, P., Gibb, W.J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G.E., Jakkula, L., Feiler, H.S., Ko, A.H., Olshen, A.B., Danenberg, K.L., Tempero, M.A., Spellman, P.T., Hanahan, D., Gray, J.W. (2011) Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nature Med. 17:500-503. PMC278279.

  • Lapuk, A., Marr, H., Jakkula, L., Pedro, H., Bhattacharya, S., Purdom, E., Hu, Z., Simpson, K., Pachter, L., Durinck, S., Wang, N., Parvin, B., Fontenay, G., Speed, T., Garbe, J., Stampfer, M., Bayandorian, H., Dorton, S., Clark, T.A., Schweitzer, A., Wyrobek, A., Feiler, H., Spellman, P., Conboy, J., Gray, J.W. (2010) Exon-level microarray analyses identify alternative splicing programs in breast cancer. Mol. Cancer Res., 8(7): 961-74. PMC2911965.

  • Verhaak, R.G., Hoadley, K.A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M.D., Miller, C.R., Ding, L., Golub, T., Mesirov, J.P., Alexe, G., Lawrence, M., O'Kelly, M., Tamayo, P., Weir, B.A., Gabriel S., Winckler, W., Gupta, S., Jakkula, L., Feiler, H.S., Hodgson, J.G., James, C.D., Sarkaria, J.N., Brennan, C., Kahn, A., Spellman, P.T., Wilson, R.K., Speed, T.P., Gray, J.W., Meyerson, M., Getz, G., Perou, C.M., Hayes, D.N. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 17(1):98-110. PMC2818769.

  • Purcell, J.W., Davis, J., Reddy, M., Martin, S., Samayoa, K., Vo, H., Thomsen, K., Bean, P., Kuo, W.-L., Ziyad, S., Billig, J., Feiler, H.S., Gray, J.W., Wood, K.W., Cases, S. (2010) Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer. Clin. Cancer Res., 16(2):566-76. PMC2844774.

Edit profile